The Incidence of Extended-spectrum β-lactamase (ESBL) Klebsiella Pneumonia in Patient on Renal Replacement Therapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoseok Koo, Inje University
ClinicalTrials.gov Identifier:
NCT01612182
First received: May 29, 2012
Last updated: June 4, 2012
Last verified: June 2012
  Purpose

The prevalence of ESBL Klebsiella pneumonia was higher in patient with renal replacement therapy.


Condition Intervention
End-stage Renal Disease
Other: renal replacement therapy

Study Type: Observational
Study Design: Time Perspective: Retrospective

Resource links provided by NLM:


Further study details as provided by Inje University:

Primary Outcome Measures:
  • The prevalence of ESBL Klebsiella pneumonia in renal replacement therapy [ Time Frame: During hospitalization ] [ Designated as safety issue: No ]
    The prevalence of ESBL Klebsiella pneumonia in renal replacement therapy during hospitalization up to 8 years (from 2004 to 2011)


Secondary Outcome Measures:
  • The prevalence of ESBL Klebsiella pneumonia in patient with pneumonia and renal replacement therapy [ Time Frame: during hospitalization ] [ Designated as safety issue: No ]
    The prevalence of ESBL Klebsiella pneumoina in patient with pneumonia and renal replacement therapy during hospitalization up to 8 years (from 2004 to 2011)


Enrollment: 1289
Study Start Date: March 2012
Study Completion Date: May 2012
Groups/Cohorts Assigned Interventions
ESBL(+) Klebsiella pneumonia
All the patient who's the culture result showed ESBL(+) Klebsiella pneumonia in any site during hospitalization
Other: renal replacement therapy
renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )
ESBL(-) Klebsiella pneumonia
All the patient who's the culture result showed ESBL(-) Klebsiella pneumonia in any site during hospitalization
Other: renal replacement therapy
renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )

  Eligibility

Ages Eligible for Study:   18 Years to 79 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The patients had admitted in single center

Criteria

Inclusion Criteria:

  • The age of patient was between 18 yrs and 79 yrs.
  • The patient who showed Klebsiella pneumonia in 1st culture result of any site during hospitalization

Exclusion Criteria:

  • The level of serum albumin was below 2.0 or over 5.0
  • The level of AST or ALT was 2 times of normal level or the level of bilirubin was over 2.0 mg/dL during 1month.
  • The level of Body mass index was below 15 or over 30
  • Pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01612182

Locations
Korea, Republic of
Inje University Seoul Paik hospital Instituional Board Review
Seoul, Je dong 2ga, Jung gu, Korea, Republic of, 100-032
Sponsors and Collaborators
Inje University
  More Information

No publications provided

Responsible Party: Hoseok Koo, Nephrology division, Department of Internal Medicine, Inje University
ClinicalTrials.gov Identifier: NCT01612182     History of Changes
Other Study ID Numbers: ESBL 2012-1
Study First Received: May 29, 2012
Last Updated: June 4, 2012
Health Authority: Korea: Food and Drug Administration

Keywords provided by Inje University:
end-stage renal disease
renal replacement therapy

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency

ClinicalTrials.gov processed this record on April 17, 2014